651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster III

A Positive Feedback Loop between YTHDC1 and EP300 Drives Tumorigenesis in Multiple Myeloma

BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Bovine Herpes Virus Type 1 Oncolytic Therapy Elicits Direct Cytotoxic Effects and Immune Microenvironment Reshaping in Multiple Myeloma

CD31 and JAM-a Expressing Circulating Tumor Plasma Cells As Prognostic Biomarkers for Multiple Myeloma Disease

CD48: Friend or Foe in NK-Cell Immunosurveillance of Multiple Myeloma?

Characterization of AT02 Bioactivity and an Assessment of Its Potential Use As an Amyloid-Clearing Therapeutic for AL Amyloidosis

Characterizing the Multiple Myeloma Bone Marrow Microenvironment at the Single-Cell Level in a Preclinical Model

DDX3X Promotes Multiple Myeloma Cell Survival and Proteasome Inhibitor Resistance through Modulation of Stress Granule Assembly and MAPKAPK2 Translation

Deciphering Variability in Light Chain Amyloidosis and Amyloidosis with Co-Occurring Multiple Myeloma By Single-Cell RNA Sequencing

Elucidation of Molecular Mechanisms of Iberdomide and Mezigdomide Resistance in Cell Line Models of Multiple Myeloma

Engineering Neutralization-Resistant Oncolytic Vaccinia Virus for Effective Treatment of Multiple Myeloma

Fatty Acid Binding Protein 6 (FABP6) Represents a Novel Target for Multiple Myeloma

Immune Profiling Reveals Distinct Features of Multiple Myeloma Subtypes Defined By Multi-Omics Network Analysis

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Non-Hotspot DIS3 Mutations in Multiple Myeloma Result in Loss of Function Accompanied By Transcriptional and Proteomic Dysregulation

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monu...

Polymerase Theta Inhibition Impairs Tumor Growth and Enhances Melphalan-Induced DNA Damage in Multiple Myeloma

Reconstructing Catastrophic Chromothripsis Events Using Multiomic Data Reveals Their Functional Impact in Multiple Myeloma

Single Cell Transcriptomics on Bone Marrow Biopsies Unveils Peculiar Bone Microenvironment Cell Subtypes and Highlights Alterations Correlated with High-Risk Features in Precursor Monoclonal Gammopathies and Multiple Myeloma Patients

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Single-Cell Profiling of ~1.7 Million Plasma Cells across 250 Individuals Reveals Transcriptional Signatures of Progression and Clonal Expansion in Multiple Myeloma and Its Precursor Stages

Subclone-Aware Prognosis across Stages of Myeloma Progression and Course of Treatment

Targeting Overexpressed IDO on Stromal Cells As a Potential Therapeutic Strategy in Multiple Myeloma

The Differential Effects of Bridging Therapy on Immune Microenvironment and Outcomes with Idecabtagene-Vicleucel in Multiple Myeloma

The Role of CST6 in Immunosuppression in the Multiple Myeloma Microenvironment

The Role of NOXA in Venetoclax Treatment Response in Multiple Myeloma

Tracking Bone Marrow Regeneration after CAR-T Cell Therapy in Myeloma at Spatial Single-Cell Resolution Reveals Determinants of Prolonged Cytopenia

Unraveling the Kinase-Independent Autoregulatory Mechanism of PIM2 in Multiple Myeloma